FSD Pharma (HUGE) and Its Rivals Critical Survey

FSD Pharma (NASDAQ: HUGE) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare FSD Pharma to similar companies based on the strength of its profitability, earnings, dividends, risk, analyst recommendations, institutional ownership and valuation.

Risk & Volatility

FSD Pharma has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500. Comparatively, FSD Pharma’s competitors have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for FSD Pharma and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FSD Pharma 0 0 1 0 3.00
FSD Pharma Competitors 136 361 413 14 2.33

As a group, “Medicinals & botanicals” companies have a potential upside of 108.41%. Given FSD Pharma’s competitors higher possible upside, analysts clearly believe FSD Pharma has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares FSD Pharma and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
FSD Pharma $190,000.00 -$39.20 million -0.39
FSD Pharma Competitors $218.50 million -$99.79 million 1.73

FSD Pharma’s competitors have higher revenue, but lower earnings than FSD Pharma. FSD Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares FSD Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FSD Pharma N/A -102.69% -88.68%
FSD Pharma Competitors -163.69% -267.59% -46.37%

Insider and Institutional Ownership

0.3% of FSD Pharma shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

FSD Pharma competitors beat FSD Pharma on 8 of the 13 factors compared.

About FSD Pharma

FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz in 1994 and is headquartered in Cobourg, Canada.

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.